DOCSLIB.ORG

Identification of Four Novel Prognosis Biomarkers and Potential Therapeutic Drugs for Human Colorectal Cancer by Bioinformatics Analysis

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Identification of Four Novel Prognosis Biomarkers and Potential Therapeutic Drugs for Human Colorectal Cancer by Bioinformatics Analysis Available online at www.jbr-pub.org.cn Open Access at PubMed Central The Journal of Biomedical Research, 2021 35(1): 21–35 Original Article Identification of four novel prognosis biomarkers and potential therapeutic drugs for human colorectal cancer by bioinformatics analysis Zhen Sun1,2, Chen Liu1, Steven Y. Cheng1,3,✉ 1Department of Medical Genetics, 2Department of Pathology and Pathophysiology, 3Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu 211166, China. Abstract Colorectal cancer (CRC) is one of the most deadly cancers in the world with few reliable biomarkers that have been selected into clinical guidelines for prognosis of CRC patients. In this study, mRNA microarray datasets GSE113513, GSE21510, GSE44076, and GSE32323 were obtained from the Gene Expression Omnibus (GEO) and analyzed with bioinformatics to identify hub genes in CRC development. Differentially expressed genes (DEGs) were analyzed using the GEO2R tool. Gene ontology (GO) and KEGG analyses were performed through the DAVID database. STRING database and Cytoscape software were used to construct a protein-protein interaction (PPI) network and identify key modules and hub genes. Survival analyses of the DEGs were performed on GEPIA database. The Connectivity Map database was used to screen potential drugs. A total of 865 DEGs were identified, including 374 upregulated and 491 downregulated genes. These DEGs were mainly associated with metabolic pathways, pathways in cancer, cell cycle and so on. The PPI network was identified with 863 nodes and 5817 edges. Survival analysis revealed that HMMR, PAICS, ETFDH, and SCG2 were significantly associated with overall survival of CRC patients. And blebbistatin and sulconazole were identified as candidate drugs. In conclusion, our study found four hub genes involved in CRC, which may provide novel potential biomarkers for CRC prognosis, and two potential candidate drugs for CRC. Keywords: colorectal cancer, Gene Expression Omnibus, biomarkers, bioinformatics analysis Introduction deaths were reported each year in the world[1]. With the understanding of pathophysiology of the disease, Nowadays, colorectal cancer (CRC) is one of the different treatment options to improve the survival most deadly cancers and almost 900 000 CRC-related rates of CRC patients have been developed in the ✉Corresponding author: Steven Y. Cheng, Department of Medical 25 August 2020; Published online: 22 October 2020 Genetics, Jiangsu Key Lab of Cancer Biomarkers, Prevention and CLC number: R735.3, Document code: A Treatment, Collaborative Innovation Center for Cancer The authors reported no conflict of interests. Personalized Medicine, Nanjing Medical University, 101 Longmian This is an open access article under the Creative Commons Attribu- Avenue, Nanjing, Jiangsu 211166, China. Tel/Fax: +86-25- tion (CC BY 4.0) license, which permits others to distribute, remix, 86869463, E-mail: [email protected]. adapt and build upon this work, for commercial use, provided the Received: 13 February 2020; Revised: 12 August 2020; Accepted: original work is properly cited. © 2021 by the Journal of Biomedical Research. https://doi.org/10.7555/JBR.34.20200021 22 Sun Z et al. J Biomed Res, 2021, 35(1) world. The 5-year survival rate of CRC patients was between CRC and normal tissues, we searched the >90% when the patients were diagnosed at early NCBI-GEO database to collect enough and adequate stages[2]. However, due to lacking early detection tissues. A total of 4 GEO datasets were selected, methods, many CRC patients were diagnosed at an including GSE113513, GSE21510, GSE44076, and advanced stage or in the metastasis status. And the 5- GSE32323. These mRNA profiles were based on year survival rate for those diagnosed with metastasis platform GPL15207 (GSE113513), GPL570 [3] was at approximately 12% . Recently, a new kind of (GSE21510 and GSE32323), and GPL13667 analysis method has been used to identify the (GSE44076). A total of 253 CRC samples and 203 differential expression genes between CRC and normal samples were chosen for this study, including normal tissues based on the high-throughput 14 pairs of cancer and normal samples in GSE113513, sequencing platforms, such as microarrays. This is a promising tool with extensive clinical applications, 124 CRC samples and 24 normal samples in including molecular diagnosis, prognosis prediction, GSE21510, 98 pairs of cancer and normal samples new drug targets discovery, etc[4–6]. Furthermore, plus 50 healthy donor tissues in GSE44076, and 17 microarray assay combining bioinformatics analysis pairs of cancer and normal samples in GSE32323. made it possible to analyze the gene expression on Identification of DEGs and data preprocessing mRNA level in CRC progression. For example, several studies have used this method to identify key To identify the DEGs, we used the NCBI-GEO2R genes in CRC development through comparing with online tool to analyze these datasets. Subsequently, normal samples, and showed that the key genes were adjusted P-value <0.05 and |log2(fold change)| >1 were involved in different signal pathways, biological set as the cutoff criteria to screen the significant DEGs processes, and molecular functions[7–12]. of each dataset. Finally, Venn diagrams were However, with a relatively limited degree of performed to get the overlap significant DEGs of the overlap, we still can not find reliable biomarkers or 4 datasets. drug targets. Therefore, the discovery of novel biomarkers for early detection and prognosis GO and KEGG pathway analyses of DEGs prediction of CRC is urgently required. To find the biological functional roles of DEGs, GO In the present study, we targeted to find key genes and KEGG pathway analyses were performed through to develop novel biomarkers or drug targets for CRC. DAVID database. Significant results of molecular Therefore, we chose four Gene Expression Omnibus function (MF), biological process (BP), cellular (GEO) datasets, GSE113513, GSE21510, GSE44076, component (CC), and biological pathways were and GSE32323, and used bioinformatics methods selected with P-value <0.05. to screen the significant differentially expressed genes (DEGs) between CRC tissues and normal PPI network construction and module analysis tissues. Gene ontology (GO) and KEGG Pathway The DEGs profiles were submitted to STRING analyses were used to find the biological roles of these database for exploring their potential interactions. DEGs through DAVID database. Furthermore, the PPI The interactions with a combined score >0.4 were network of DEGs was constructed and key modules or considered significant. Subsequently, the interaction hub genes were selected with Molecular Complex Detection (MCODE) plugin of Cytoscape software. files were downloaded and imported into Cytoscape And the clinical significance was validated by GEPIA software to construct the PPI network. The MCODE database. Finally, small active candidate molecules plugin was used to find key modules of the whole PPI were identified to develop new drugs through network with a degree cutoff=2, node score Connectivity Map (CMap) database. In brief, we cutoff=0.2, K-core=2, and max depth=100. The found four hub genes involved in CRC, which may hub genes were then selected with connectivity provide novel potential biomarkers for CRC degree >10. Furthermore, KEGG pathway analyses of prognosis, and two potential candidate drugs for CRC. the significant modules were performed with P-value <0.05. Materials and methods Analysis and validation of hub genes Data resources To verify the hub genes we found, we used GEPIA To explore the differential gene expression profiles database to analyze their expression and clinical Novel prognosis biomarkers and drugs for colorectal cancer 23 prognostic information in 270 CRC patients. And the edges (Fig. 3). Based on degree scores using the survival curve, stage analysis and box plot were MCODE plugin, two key modules were detected from performed to show the clinical implications of the whole PPI network complex. Module 1 contained hub genes. 61 nodes and 1648 edges, and DEGs were enriched in cell cycle, oocyte meiosis, progesterone-mediated Identification of small molecules oocyte maturation, DNA replication and p53 signaling To find potential small active molecules to develop pathway (Fig. 4A and B). Module 2 had 55 nodes and new drugs for treating CRC, we uploaded DEGs 625 edges, and these DEGs were enriched in probe profiles into the CMap database. This database chemokine signaling pathway, ribosome biogenesis in can help to predict small molecules that induce or eukaryotes, cytokine-cytokine receptor interaction, reverse gene expression signature with a score from pathways in cancer, purine metabolism, RNA −1 to 1. And the molecules which value from 0 closer polymerase, retrograde endocannabinoid signaling, TNF signaling pathway, legionellosis, regulation of to −1 were functioned as reversing the cancer cell status. lipolysis in adipocytes, NOD-like receptor signaling Results pathway, cytosolic DNA-sensing pathway and gastric acid secretion (Fig. 4C and D). Additionally, the top Identification of DEGs in CRC 20 hub genes, CDK1, CCNB1, MYC, CCNA2, MAD2L1, AURKA, TOP2A, CDC6, UBE2C, CHEK1, Analyzed with the GEO2R online tool, a total of RRM2, BUB1B, TTK, TRIP13, TPX2, BUB1, NCAPG, 1763, 4411, 2428, and 2276 DEGs were extracted KIF2C, KIF23, and MCM4 were identified with from GSE113513,
Load more

Recommended publications
  • LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll
    LIGAND FORMULA INDEX CH5N 1 C3HllN3 68 CH 0 NP Z97 6 3 C3Hll °3Nl 304 C3HIZ0gNP3 319 C H O N 164 Z 3 Z 3 C3HIZ0l0NP3 3Z0 CZH4OZN4 164 C H N 335 Z 5 C4H304N3 343 C H 0 N 347 Z 5 Z Z C4H4NZ 263,263,264 C H 0N Z6 Z 6 Z C4H402N2 34Z C H O N Z 6 Z 4 56 C4H403NZ 34Z C H N Z,72 2 7 C4H5ON Z 264 C H NS 3Z Z 7 C4H6NZ 146,148,149,349 C H 0N 15 Z 7 C4H6ON Z 15Z,15Z C H 0 NS 10 Z 7 3 C4H7N3 155 C H 0 NS 331 Z 7 4 C4H9N 7,73 C H N 36 2 8 Z C4HgN3 S2 348 C H 0 NP Z 8 3 Z98,246 C4HgON 81 C H 0 NP 3Z9 Z 8 4 C4HgON 2 348 C4HgOZN Z4,333,333 C H N 144,349 3 4 Z C4HgOZNS 33 C3H7N 6,331,335 C4H9OZN3 28,348 C H 0 N 23 3 7 2 C4Hg03 N 18 C3H80N 79 C4H904N2 77 Z7,3L,7 C3H80N2 C4H10NZ 91 3,331 C3HgN C4Hl00ZNZ 59 33,%7 C3H9NS C4H1006NP 346 347 C3HgN3 S C4HllN 3,5,7Z,331,331 C H ON 3 g 16,16,21 C4Hll NS 348 C H O N 347 3 g Z C4HllON 17,79,115,33Z,33Z,347 10 C3Hg03 NS C4HllONS 35 C H N 39,51,8Z 3 10 Z C4HllOZN 19,80 C H ON 57 3 10 Z C4Hl103N ZO 298,300,301 C3HIOO3 NP C4Hll03NS 11 393 394 LIGAND FORMULA INDEX C4H1ZN2 40,40,41,42,S2,S4,83,88,lZ0 CsHn 02N3 29,29 C4H12N2S 6S C5H12NZ 91,92,124 C4H12NZS2 66 CSH120NZ 14 C4H1ZON 2 S8,9S CSH1202NZ 334 C4H1Z03NP Z99,346 CSH13N 4,331,33S C4H13N3 69,101 CSH130N 17,337 C4H1306NPZ 318 CSH130ZN 117,336,347 C4H1404Nl2 Z93 CSH1303NS 11 C4H1406NZPZ 30S CSH14NZ S3,SS,84,84,92,337 CSH140N Z 96,97,348,348 CSH3N4Cl 344 CSH1403NP 317,346 CSH4NBr 340,340 CSH140SNP 317 CSH4NCI 340,340 CSHlSN3 103,103 CSH4N4 344 CSH16 N4 71 CSH4N4S 344 CSH1709Nl3 346 CSH40N4 34S CSH40ZN4 34S C6H4N2 177,177 CSHSN 16S C6H4ON4 3S3 CSHSNS 276 C6H402N4 3S3 CSHSNSS
    [Show full text]
  • Réglementation De La Pharmacie
    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
    [Show full text]
  • 29. Produits Chimiques Organiques
    29 Chapitre 29 Produits chimiques organiques Considérations générales Le Chapitre 29 ne comprend, en principe, que des composés de constitution chimique dé- finie présentés isolément, sous réserve toutefois des dispositions de la Note 1 du Chapitre. A) Composés de constitution chimique définie (Note 1 du Chapitre) Un composé de constitution chimique définie présenté isolément est une substance consti- tuée par une espèce moléculaire (covalente ou ionique, notamment) dont la composition est définie par un rapport constant entre ses éléments et qui peut être représentée par un diagramme structural unique. Dans un réseau cristallin, l'espèce moléculaire correspond au motif répétitif. Les composés de constitution chimique définie présentés isolément contenant des subs- tances qui ont été ajoutées délibérément pendant ou après leur fabrication (y compris la purification) sont exclus du présent Chapitre. Par conséquent, un produit constitué par exemple par de la saccharine mélangée avec du lactose afin qu'il puisse être utilisé comme édulcorant, est exclu du présent Chapitre (voir la Note explicative du no 2925). Ces composés peuvent contenir des impuretés (Note 1 a). Le libellé du no 2940 fait excep- tion à cette règle car, en ce qui concerne les sucres, il restreint la portée de la position aux sucres chimiquement purs. Le terme "impuretés" s'applique exclusivement aux substances dont la présence dans le composé chimique distinct résulte exclusivement et directement du procédé de fabrication (y compris la purification). Ces substances peuvent résulter de l'un quelconque des élé- ments intervenant au cours de la fabrication, et qui sont essentiellement les suivants: a) matières de départ non converties, b) impuretés se trouvant dans les matières de départ, c) réactifs utilisés dans le procédé de fabrication (y compris la purification), d) sous-produits.
    [Show full text]
  • 付表 ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated
    付表ⅠA 指定を受けた医薬の有効成分 Annex ⅠA Designated Pharmaceutical Active Ingredients 号(Sub-heading) 品名 Description 2818.30 アルゲルドラート algeldrate 2833.22 アルスルフ alusulf 2842.10 アルマシラート almasilate 2842.10 シマルドラート simaldrate 2842.90 硫酸アルマドラ ート almadrate sulfate 2842.90 アルマガート almagate 2842.90 カルバルドラード carbaldrate 2842.90 ヒドロタルシト hydrotalcite 2842.90 マガルドラート magaldrate 2843.30 オーラノフィン auranofin 2843.30 金チオグリカニド aurothioglycanide 2843.30 金チオりんご酸ナトリウム sodium aurothiomalate 2843.30 金チオ硫酸ナトリウム sodium aurotiosulfate 2843.90 カルボプラチン carboplatin 2843.90 シスプラチン cisplatin 2843.90 デキソルマプラチン dexormaplatin 2843.90 エンロプラチン enloplatin 2843.90 イプロプラチン iproplatin 2843.90 ロバプラチン lobaplatin 2843.90 ミボプラチン miboplatin 2843.90 ネダプラチン nedaplatin 2843.90 オルマプラチン ormaplatin 2843.90 オキサリプラチン oxaliplatin 2843.90 セブリプラチン sebriplatin 2843.90 スピロプラチン spiroplatin 2843.90 ゼニプラチン zeniplatin 2844.40 アルツモマブ altumomab 2844.40 塩化セシウム(131Cs) cesium (131 Cs) chloride 2844.40 クロルメロドリン(197Hg) chlormerodrin (197 Hg) 2844.40 シアノコバラミン(57Co) cyanocobalamin (57 Co) 2844.40 シアノコバラミン(58Co) cyanocobalamin (58 Co) 2844.40 シアノコバラミン(60Co) cyanocobalamin (60 Co) 2844.40 エチオダイズド油(131I) ethiodized oil (131 I) 2844.40 くえん酸第二鉄(59Fe)注射液 ferric (59 Fe) citrate in 2844.40 フィブリノゲン(125I) fibrinogen (125 I) 2844.40 フルデオキシグルコー ス(18F) fludeoxyglucose ( 18 F) 2844.40 フルオロドパ(18F) fluorodopa (18 F) 2844.40 くえん酸ガリウム(67Ga) gallium (67 Ga) citrate 2844.40 金コロイド(198Au) gold (198 Au), colloidal 2844.40 イオベングアン(131I) iobenguane (131 I) 2844.40 よう化人血清アルブミン(125I) iodinated (125 I) human serum albumin 2844.40 よう化人血清アルブミン(131I) iodinated
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Cardiac Ryr N-Terminal Region Biosensors for FRET-Based High-Throughput Screening
    bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Cardiac RyR N-terminal region biosensors for FRET-based high-throughput screening Jingyan Zhang1, Siobhan M. Wong King Yuen,2 Jacob A. Schwarz1, Levy M. Treinen1, Ching-Chieh Tung2, Robyn T. Rebbeck1, Kaja Berg3, Bengt Svensson1, Courtney C. Aldrich3, David D. Thomas1, Filip Van Petegem2, and Razvan L. Cornea1* 1Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, Minneapolis, MN 55455, USA. 2Department of Biochemistry and Molecular Biology, Life Sciences Institute, University of British Columbia,V6T 1Z3 Vancouver, BC, Canada. 3Department of Medicinal Chemistry, University of Minnesota, Minneapolis, MN, 55455, USA. Corresponding author: Razvan L. Cornea Email: [email protected] Running title: FRET biosensor constructs for RyR-targeted drug discovery Keywords: Ryanodine receptor; N-terminal region; FRET; fluorescence lifetime; high-throughput screening; myopathy. bioRxiv preprint doi: https://doi.org/10.1101/2021.02.07.430153; this version posted February 10, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract failure (HF) (9-13). Physiologically, the opening and closing of RyR channels are tightly regulated The N-terminal region (NTR) of the ryanodine by small molecules, ions, and proteins(14), many receptor (RyR) calcium channels is critical to the of them binding to the enormous RyR cytoplasmic 2+ regulation of Ca release during excitation- portion, with functional effects allosterically contraction coupling.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • I (Acts Whose Publication Is Obligatory) COMMISSION
    13.4.2002 EN Official Journal of the European Communities L 97/1 I (Acts whose publication is obligatory) COMMISSION REGULATION (EC) No 578/2002 of 20 March 2002 amending Annex I to Council Regulation (EEC) No 2658/87 on the tariff and statistical nomenclature and on the Common Customs Tariff THE COMMISSION OF THE EUROPEAN COMMUNITIES, Nomenclature in order to take into account the new scope of that heading. Having regard to the Treaty establishing the European Commu- nity, (4) Since more than 100 substances of Annex 3 to the Com- bined Nomenclature, currently classified elsewhere than within heading 2937, are transferred to heading 2937, it is appropriate to replace the said Annex with a new Annex. Having regard to Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Com- mon Customs Tariff (1), as last amended by Regulation (EC) No 2433/2001 (2), and in particular Article 9 thereof, (5) Annex I to Council regulation (EEC) No 2658/87 should therefore be amended accordingly. Whereas: (6) This measure does not involve any adjustment of duty rates. Furthermore, it does not involve either the deletion of sub- stances or addition of new substances to Annex 3 to the (1) Regulation (EEC) No 2658/87 established a goods nomen- Combined Nomenclature. clature, hereinafter called the ‘Combined Nomenclature’, to meet, at one and the same time, the requirements of the Common Customs Tariff, the external trade statistics of the Community and other Community policies concerning the (7) The measures provided for in this Regulation are in accor- importation or exportation of goods.
    [Show full text]
  • The Inhibition of Noradrenaline Uptake by Sympathomimetic Amines in the Rat Isolated Heart
    Brit. J. Pharmacol. (1965), 25. 34-49. THE INHIBITION OF NORADRENALINE UPTAKE BY SYMPATHOMIMETIC AMINES IN THE RAT ISOLATED HEART BY A. S. V. BURGEN AND L. L. IVERSEN From the Department ofPharmacology, University of Cambridge (Received August 30, 1964) -In the rat isolated heart, noradrenaline can be accumulated by two distinct processes. The first process (Uptake1) is half saturated at a (±)-noradrenaline concentration of 0.11 pg/ml. and continues to operate at external noradrenaline concentrations up to 1 ,ug/ml. (Iversen, 1963). The second process comes into play at slightly higher concentra- tions and becomes half saturated at 42.6 ,ug/ml. (Iversen, 1965b). Both of these processes act also upon adrenaline, which competes for uptake when noradrenaline is also present (Iversen, 1965a, b). It seems probable, therefore, that other sympathomimetic amines would have an affinity for the systems operative in accumulation, and indeed, there is some evidence in the literature that amphetamine, tyramine and ephedrine inhibit noradrenaline uptake (Dengler, Spiegel & Titus, 1961; Axelrod & Tomchick, 1960). This paper is concerned with the measurement of the affinity of sympathomimetic amines for the uptake system as measured by inhibition of noradrenaline accumulation. Needless to say, the demonstration that a substance inhibits noradrenaline uptake does not prove that it is also transported by the system; this would require a direct measurement of the accumulation of the substance in the tissue. A preliminary account of some of these results has already been published (Iversen, 1964). METHODS Inhibition of UptakeL In control experiments, hearts were perfused with a medium containing (±)-[_4C]noradrenaline (Nichem Inc., Bethesda, Maryland, U.S.A.) at a concentration of 10 ng/ml.
    [Show full text]
  • Council of Europe Committee of Ministers (Partial
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies and superseding Resolution AP (77) 1) AND APPENDIX containing the list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 31 October 1982 RESOLUTION AP (82) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION 1 (Adopted by the Committee of Ministers on 2 June 1982 at the 348th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands, the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969 and 5 May 1964, respectively, Considering that, under the terms of its Statute, the aim of the Council of Europe is to achieve a greater unity between its Members for the purpose of safeguarding and realising the ideals and principles which are their common heritage and facilitating their economic and social progress; Having regard to the
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2005/0043408A1 Yeboah Et Al
    US 2005.0043408A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2005/0043408A1 Yeboah et al. (43) Pub. Date: Feb. 24, 2005 (54) ANTI-GLYCATION AGENTS FOR Related U.S. Application Data PREVENTINGAGE- DIABETES- AND SMOKING-RELATED COMPLICATIONS (60) Provisional application No. 60/328,808, filed on Oct. 15, 2001. (76) Inventors: Faustinus Yeboah, Longueuil (CH); Publication Classification Yasuo Konishi, Kirkland (CA); Sung Ju Cho, Montreal (CA); Jittiwud (51) Int. Cl." ...................... A61K 31/195; CO7C 31/137 Lertvorachon, Montreal (CA); Taira (52) U.S. Cl. ........................... 514/567; 514/649; 514/651 Kiyota, St. Laurent (CA); Popek Tomasz, Pointe-Claire (CA) (57) ABSTRACT The invention provides new inhibitors of protein glycation, Correspondence Address: identified from compound libraries by a high throughput BORDEN LADNER GERVAS LLP Screening assay. The anti-glycation agents So identified are WORLD EXCHANGE PLAZA characterized by a variety of chemical Structures and are 100 QUEEN STREETSUITE 1100 useful for the prevention or treatment of age-, diabetes-, and OTTAWA, ON K1P 1J9 (CA) Smoking-related complications, including neuropathy, neph ropathy, ocular pathologies, or the loSS of mechanical prop erties of collagenous tissues. Among compounds identified (21) Appl. No.: 10/492,553 as having the anti-glycation activity, of Special interest are epinephrine and its analogs, in particular D-epinephrine and (22) PCT Filed: Oct. 15, 2002 its analogs, which are particularly useful for the prevention or treatment of age-, diabetes-, and Smoking-related ocular (86) PCT No.: PCT/CA02/01552 pathologies. Patent Application Publication Feb. 24, 2005 Sheet 1 of 2 US 2005/0043408 A1 100 L-Norepinephrine IC50=59 uM 8 O 60 | 4.O 2 O Log inhibitor FIG.
    [Show full text]
  • Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes
    Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2004) -- Supplement 1 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC ACID 26976-72-7
    [Show full text]